NMS Capital has exited its investment in Flourish Research, a US-based clinical trial organization, through a sale to Genstar Capital. No financial terms were disclosed.

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report) today and set a price target ...

LifeSci Capital analyst Anshul Dhankher maintained a Buy rating on Perspective Therapeutics (CATX – Research Report ... The company has shown consistent execution in its clinical programs, ...

Experts have identified a cannabis compound called cannabinol (CBN) that appears to significantly enhance sleep quality.

Original research ranges from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative ...

More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and ...

The project includes the establishment of a Research and Innovation Centre. Construction has commenced on the redevelopment ...

With innovative clinical research services and custom-tailored solutions, Ergomed ensures that oncology treatments progress ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

Phase 1: Discovery and Preclinical Phases: Identification and testing of potential drug compounds. Duration: 1 to 6 years.